Amrubicin

Search with Google Search with Bing

Information
Drug Name
Amrubicin
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung cancer NQO1 EXPRESSION NQO1 EXPRESSION D Predictive Supports Resistance N/A 2 21964527 Detail
lung cancer NQO1 p.Pro187Ser (p.P187S)
( ENST00000439109.6, ENST00000379046.6, ENST00000379047.7, ENST00000564043.1, ENST00000320623.10, ENST00000561500.5 ) NQO1 p.Pro187Ser (p.P187S)
( ENST00000320623.10, ENST00000379046.6, ENST00000379047.7, ENST00000439109.6, ENST00000561500.5, ENST00000564043.1 ) 		D Predictive Supports Sensitivity/Response Common Germline 2 21964527 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Higher expression of NQO1 was correlated with decr... NQO1 NQO1 EXPRESSION NQO1 EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
The presence of NQO1 C609T SNP (rs1800566) was ass... NQO1 NQO1 p.Pro187Ser (p.P187S)
( ENST00000439109.6, ENST00000379046.6, ENST00000379047.7, ENST00000564043.1, ENST00000320623.10, ENST00000561500.5 ) NQO1 p.Pro187Ser (p.P187S)
( ENST00000320623.10, ENST00000379046.6, ENST00000379047.7, ENST00000439109.6, ENST00000561500.5, ENST00000564043.1 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT00319969 Completed Phase 2 Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. April 2006 January 2009
NCT00375193 Completed Phase 2 Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy November 1, 2006 March 1, 2009
NCT01259375 Completed Phase 2 Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma September 2011 February 2016
NCT01355705 Completed Phase 1/Phase 2 Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma August 2011 July 2017
NCT01364727 Completed Phase 2 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies June 2011 December 31, 2018
NCT02481830 Completed Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer September 14, 2015 August 30, 2022
NCT00388960 Completed Phase 2 Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer November 1, 2006 December 1, 2010
NCT00547651 Completed Phase 3 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy September 1, 2007 May 1, 2011
NCT00890955 Completed Phase 1 Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies March 2009 July 2010
NCT00915083 Completed Phase 1 A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors. June 1, 2009 May 1, 2011
NCT01033032 Completed Phase 1/Phase 2 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer December 2009 October 2014
NCT01076504 Completed Phase 2 A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer December 2009 March 2015
NCT06203210 Not yet recruiting Phase 3 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer June 10, 2024 February 22, 2029
NCT05740566 Recruiting Phase 3 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer May 31, 2023 August 1, 2027
NCT01331824 Terminated Phase 2 Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma February 2011 July 2015
NCT00380835 Withdrawn Phase 2 Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer December 2007